About Orexigen Therapeutics
Orexigen Therapeutics is a company based in San Diego (United States) founded in 2002. Orexigen Therapeutics has raised $76 million across 7 funding rounds from investors including Kleiner Perkins, Duke University and The Baupost Group. The company has 132 employees as of December 31, 2016. Orexigen Therapeutics operates in a competitive market with competitors including Adocia, Altimmune, Carmot, BioAge Labs and Fractyl, among others.
- Headquarter San Diego, United States
- Employees 132 as on 31 Dec, 2016
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Orexigen Therapeutics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$76 M (USD)
in 7 rounds
-
Latest Funding Round
$49.6 M (USD), Post-IPO
Feb 23, 2017
-
Investors
Kleiner Perkins
& 8 more
-
Employee Count
132
as on Dec 31, 2016
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Orexigen Therapeutics
Orexigen Therapeutics has successfully raised a total of $76M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $49.6 million completed in February 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 7
- Last Round Post-IPO — $49.6M
-
First Round
First Round
(21 Jan 2004)
- Investors Count 9
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb, 2017 | Amount | Post-IPO - Orexigen Therapeutics | Valuation |
investors |
|
| Mar, 2016 | Amount | Post-IPO - Orexigen Therapeutics | Valuation |
investors |
|
| Sep, 2015 | Amount | Post-IPO - Orexigen Therapeutics | Valuation |
investors |
Investors in Orexigen Therapeutics
Orexigen Therapeutics has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Kleiner Perkins, Duke University and The Baupost Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital investments are offered to startups by NEA.
|
Founded Year | Domain | Location | |
|
Life science & tech focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Growth capital investments are made in healthcare and fintech companies.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Orexigen Therapeutics
Financial Statements - Orexigen Therapeutics
Orexigen Therapeutics Comparisons
Competitors of Orexigen Therapeutics
Orexigen Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Adocia, Altimmune, Carmot, BioAge Labs and Fractyl, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| domain | founded_year | HQ Location |
Vaccines for infectious diseases and solid tumors are developed.
|
|
| domain | founded_year | HQ Location |
Disease-modifying therapies for metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Bioinformatics platform is provided for biomarkers and drug discovery.
|
|
| domain | founded_year | HQ Location |
Endoscopic procedures for type-2 diabetes treatment are developed.
|
|
| domain | founded_year | HQ Location |
Peptide-based therapies for obesity and cardiometabolic disorders are developed.
|
Frequently Asked Questions about Orexigen Therapeutics
Orexigen Therapeutics was founded in 2002 and raised its 1st funding round 2 years after it was founded.
Orexigen Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Orexigen Therapeutics is a funded company, having raised a total of $76M across 7 funding rounds to date. The company's 1st funding round was a Post-IPO of $60M, raised on Jan 21, 2004.
As of Dec 31, 2016, the latest employee count at Orexigen Therapeutics is 132.
Orexigen Therapeutics was founded in 2002 and is headquartered in San Diego, United States. The company operates in the pharmaceutical sector, with a focus on obesity management. Its primary product, Contrave (naltrexone HCl and bupropion HCl extended release), received approval in the US in September 2014. In Europe, the same drug is marketed as Mysimba (naltrexone HClbupropion HCl prolonged release). Operations center on drug development and commercialization for obesity-related conditions.
Orexigen Therapeutics's top competitors include Adocia, BioAge Labs and Fractyl.
Orexigen Therapeutics has 9 investors. Key investors include Kleiner Perkins, Duke University, The Baupost Group, NEA, and Wasatch Advisors.